Cumberland Pharmaceuticals (NASDAQ:CPIX) Announces Earnings Results

Cumberland Pharmaceuticals (NASDAQ:CPIX) issued its quarterly earnings data on Tuesday. The specialty pharmaceutical company reported ($0.01) earnings per share for the quarter, FiscalAI reports. Cumberland Pharmaceuticals had a negative net margin of 8.06% and a positive return on equity of 5.13%. The company had revenue of $13.68 million for the quarter.

Here are the key takeaways from Cumberland Pharmaceuticals’ conference call:

• Fourth-quarter revenue was $13.7M (+31% YoY) and full-year revenue was $44.5M (+18%), with adjusted earnings of $1.7M ($0.11/share) and operating cash flow of ~$4.9M, reflecting a commercial turnaround and double-digit growth for 2025.
• Ifetroban delivered breakthrough Phase II FIGHT DMD results (high-dose improved LVEF vs placebo and natural-history controls) and has Orphan, Rare Pediatric and Fast Track FDA designations as Cumberland pursues registration for DMD-associated cardiomyopathy.
• Cumberland expanded international reach with Vibativ approval in China, a launch in Saudi Arabia and regulatory approval for its ibuprofen injection in Mexico, plus a $3M China milestone payment supporting global growth.
• The company added Talicia via a joint venture with RedHill (Talicia Holdings, Inc.), began U.S. co-commercialization and now supports its brands with a 50-person national sales and medical organization, broadening its US commercial footprint.
• Despite progress, Cumberland posted a $2.9M full-year net loss and rising operating expenses ($47.3M); acquired brands added large purchase prices but year-end estimated values (~$10M each) and total cash of $11.4M highlight potential asset-valuation and liquidity risks.

Cumberland Pharmaceuticals Stock Performance

Shares of CPIX opened at $4.64 on Wednesday. The firm has a market cap of $69.41 million, a PE ratio of -19.33 and a beta of -0.58. The stock’s fifty day moving average price is $4.18 and its two-hundred day moving average price is $3.42. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.23 and a quick ratio of 1.11. Cumberland Pharmaceuticals has a 1 year low of $1.85 and a 1 year high of $7.25.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Cumberland Pharmaceuticals to a “hold” rating in a report on Saturday, January 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Institutional Investors Weigh In On Cumberland Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. XTX Topco Ltd purchased a new position in shares of Cumberland Pharmaceuticals in the second quarter worth about $34,000. Heron Bay Capital Management purchased a new position in Cumberland Pharmaceuticals in the 2nd quarter valued at approximately $111,000. Two Sigma Investments LP grew its stake in Cumberland Pharmaceuticals by 16.5% in the 3rd quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock valued at $117,000 after buying an additional 5,326 shares in the last quarter. Marshall Wace LLP bought a new stake in Cumberland Pharmaceuticals during the 4th quarter valued at $192,000. Finally, Geode Capital Management LLC lifted its position in shares of Cumberland Pharmaceuticals by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 107,274 shares of the specialty pharmaceutical company’s stock worth $427,000 after acquiring an additional 5,653 shares in the last quarter. 15.51% of the stock is owned by hedge funds and other institutional investors.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.